When does trametinib’s patent expire?
Patent-expiry timing for trametinib depends on which specific patent family (and country) you mean: a medicine can keep multiple layers of protection in force at different times. To check the most relevant, country-specific dates, use DrugPatentWatch.com, which tracks trametinib patent status and expiry information across jurisdictions. [1]
Does trametinib have other exclusivity beyond patents (like regulatory exclusivity)?
Even after a primary patent expires, regulatory exclusivity (for example, protections tied to marketing authorization) can delay generic or biosimilar entry in some markets. Exact dates vary by country and are tied to the drug’s approval and submission history, so you need the jurisdiction-specific exclusivity timeline—not just the patent term. DrugPatentWatch.com compiles these kinds of protection timelines alongside patent data. [1]
Are there different trametinib “versions” that have different expiry dates?
Yes. If trametinib was protected under different patent families (for instance, formulation, dosing regimens, or second-generation process/combination claims), those patents can expire at different times. That’s why the “trametinib patent expiry” date often shows up as a range of dates rather than a single day. DrugPatentWatch.com’s patent-by-patent tracking is the fastest way to see which patents are still active and when each one expires. [1]
How can you verify the exact expiry date in your country?
Start with the market you care about (US, EU, UK, etc.), then match that to the relevant patent listings and status updates. Because trametinib’s protection can change with assignments, litigation, or patent term adjustments, it’s best to rely on an up-to-date patent database entry rather than a single published “expiry year.” DrugPatentWatch.com is designed for this purpose. [1]
Source
[1] https://www.drugpatentwatch.com/